| I believe ELAN is a worthy candidate to add to your watchlist for a number of reasons. Elanco is a global leader in animal health, providing a wide range of products for both pets and livestock. Their pipeline is particularly strong, focusing on high-demand areas like pet parasiticides, dermatology treatments, and alternatives to antibiotics in livestock. With innovative products like Credelio Quattro for pets and Increxxa for farm animals in development or expansion, Elanco is well-positioned to capitalize on growing market needs. This robust pipeline, combined with their commitment to sustainability and digital health solutions, suggests significant growth potential in the animal health sector. Now, the last time its CEO bought shares in the open market was March 10, 2023. His average price for that purchase was $9.59. Within five months from that purchase shares shot up by 30%. And a year later they were up 88%. It's hard to bet against him based on that track record. Action Plan: Keep an eye on ELAN and look for a potential entry on a pullback. Shares shot up significantly on Tuesday following the insider buy, but based on the CEO's track record, this could just be the start of a bigger move. Trading with an edge is critical in this market, and that's why we track and trade off insider activity in The War Room. If you'd like to learn more about what we're doing in the portfolio, make sure to click here to find out. | 
No comments:
Post a Comment